Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) CFO John Alexander Kelly bought 2,113 shares of the firm's stock in a transaction on Friday, December 27th. The stock was bought at an average price of $4.75 per share, with a total value of $10,036.75. Following the completion of the purchase, the chief financial officer now owns 40,186 shares of the company's stock, valued at $190,883.50. This trade represents a 5.55 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Precision BioSciences Trading Down 10.6 %
Shares of NASDAQ DTIL opened at $3.81 on Wednesday. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $19.43. The company has a market cap of $29.23 million, a price-to-earnings ratio of 63.51 and a beta of 1.41. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The stock's 50 day simple moving average is $6.69 and its 200 day simple moving average is $8.54.
Institutional Investors Weigh In On Precision BioSciences
A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC boosted its position in Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) by 10.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 702,069 shares of the company's stock after purchasing an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent quarter. 37.99% of the stock is owned by institutional investors.
About Precision BioSciences
(
Get Free Report)
Buy this coin BEFORE Inauguration Day …
From Weiss Ratings | Ad
Mark my words … Bitcoin is going to $100,000.
BEFORE Trump is inaugurated.
And I think it could reach $125,000 by the end of his first month in office.
This could be his favorite coin.
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
